Mydecine Innovations Group cultivating low-cost psilocybin mushrooms at scale to treat PTSD

‍

Mydecine Innovations Group (CSE:MYCO) (OTCMKTS:MYCOF) CEO Joshua Bartch tells Proactive the Colorado-based emerging biotech and life sciences company is advancing towards a Phase 2 study to treat PTSD with its ‘purified’ psilocybin mushrooms.

Bartch says the group recently produced its first commercial harvest of 20 kilograms of psilocybin mushrooms at a private research and cultivation facility in Jamaica, which was exported into Canada at the University of Alberta.

Watch video below:

‍

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Mydecine Innovations Group cultivating low-cost psilocybin mushrooms at scale to treat PTSD

DailyMushroom

© 2024 DAILY MUSHROOM. All Rights Reserved